Cargando…

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

This study was performed with the aim of discovering the characteristics and survival of patients with metastatic renal carcinoma who undergo immunotherapy with an Interleukin 2 based regimen. One hundred and eighty-one patients with metastatic renal carcinoma were referred to our institute from Oct...

Descripción completa

Detalles Bibliográficos
Autores principales: Philip, T., Negrier, S., Lasset, C., Coronel, B., Bret, M., Blay, J. Y., Merrouche, Y., Carrie, C., Kaemmerlen, P., Chauvin, F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968726/
https://www.ncbi.nlm.nih.gov/pubmed/8217594
_version_ 1782134803587399680
author Philip, T.
Negrier, S.
Lasset, C.
Coronel, B.
Bret, M.
Blay, J. Y.
Merrouche, Y.
Carrie, C.
Kaemmerlen, P.
Chauvin, F.
author_facet Philip, T.
Negrier, S.
Lasset, C.
Coronel, B.
Bret, M.
Blay, J. Y.
Merrouche, Y.
Carrie, C.
Kaemmerlen, P.
Chauvin, F.
author_sort Philip, T.
collection PubMed
description This study was performed with the aim of discovering the characteristics and survival of patients with metastatic renal carcinoma who undergo immunotherapy with an Interleukin 2 based regimen. One hundred and eighty-one patients with metastatic renal carcinoma were referred to our institute from October 1987 until August 1991; 129 were treated with Interleukin 2 with or without Interferon alpha in three successive protocols. Fifty-two patients were not treated with immunotherapy due to the exclusion criteria of the protocols. Sixty-four patients with the same disease who had been referred to our institute before the initiation of this programme (1982, 1987) were also analysed as a control group. The main characteristics of the three different cohorts of patients were analysed and compared with univariate statistical tests; the median survival of the patients was calculated and compared. The referral rate increased from 13 a year to 45 a year while the IL2 trials were being conducted. Patients treated with cytokines have a median survival of 18 months after occurrence of metastases, compared to 6 and 8 months, respectively, in excluded patients and the control group. This parameter is of 15 months when the 181 patients, treated with cytokines or not, are considered. The survival of treated vs excluded patients is significantly different (P < 10(-6); so is the survival of the 181 patients recently included when compared to the historical group (P:10(-5). When the 181 recent patients are compared to the historical control group, a number of differences appear in their characteristics, which prevent us from drawing any conclusion about the role of immunotherapy in the improvement of survival observed. This study clearly evidences the selection of the patients receiving immunotherapy and the modification in referrals of a disease induced by a new available therapy. This emphasises the need for prospective studies in this setting.
format Text
id pubmed-1968726
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19687262009-09-10 Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients. Philip, T. Negrier, S. Lasset, C. Coronel, B. Bret, M. Blay, J. Y. Merrouche, Y. Carrie, C. Kaemmerlen, P. Chauvin, F. Br J Cancer Research Article This study was performed with the aim of discovering the characteristics and survival of patients with metastatic renal carcinoma who undergo immunotherapy with an Interleukin 2 based regimen. One hundred and eighty-one patients with metastatic renal carcinoma were referred to our institute from October 1987 until August 1991; 129 were treated with Interleukin 2 with or without Interferon alpha in three successive protocols. Fifty-two patients were not treated with immunotherapy due to the exclusion criteria of the protocols. Sixty-four patients with the same disease who had been referred to our institute before the initiation of this programme (1982, 1987) were also analysed as a control group. The main characteristics of the three different cohorts of patients were analysed and compared with univariate statistical tests; the median survival of the patients was calculated and compared. The referral rate increased from 13 a year to 45 a year while the IL2 trials were being conducted. Patients treated with cytokines have a median survival of 18 months after occurrence of metastases, compared to 6 and 8 months, respectively, in excluded patients and the control group. This parameter is of 15 months when the 181 patients, treated with cytokines or not, are considered. The survival of treated vs excluded patients is significantly different (P < 10(-6); so is the survival of the 181 patients recently included when compared to the historical group (P:10(-5). When the 181 recent patients are compared to the historical control group, a number of differences appear in their characteristics, which prevent us from drawing any conclusion about the role of immunotherapy in the improvement of survival observed. This study clearly evidences the selection of the patients receiving immunotherapy and the modification in referrals of a disease induced by a new available therapy. This emphasises the need for prospective studies in this setting. Nature Publishing Group 1993-11 /pmc/articles/PMC1968726/ /pubmed/8217594 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Philip, T.
Negrier, S.
Lasset, C.
Coronel, B.
Bret, M.
Blay, J. Y.
Merrouche, Y.
Carrie, C.
Kaemmerlen, P.
Chauvin, F.
Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.
title Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.
title_full Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.
title_fullStr Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.
title_full_unstemmed Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.
title_short Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.
title_sort patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. analysis of a single institution study on 181 patients.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968726/
https://www.ncbi.nlm.nih.gov/pubmed/8217594
work_keys_str_mv AT philipt patientswithmetastaticrenalcarcinomacandidateforimmunotherapywithcytokinesanalysisofasingleinstitutionstudyon181patients
AT negriers patientswithmetastaticrenalcarcinomacandidateforimmunotherapywithcytokinesanalysisofasingleinstitutionstudyon181patients
AT lassetc patientswithmetastaticrenalcarcinomacandidateforimmunotherapywithcytokinesanalysisofasingleinstitutionstudyon181patients
AT coronelb patientswithmetastaticrenalcarcinomacandidateforimmunotherapywithcytokinesanalysisofasingleinstitutionstudyon181patients
AT bretm patientswithmetastaticrenalcarcinomacandidateforimmunotherapywithcytokinesanalysisofasingleinstitutionstudyon181patients
AT blayjy patientswithmetastaticrenalcarcinomacandidateforimmunotherapywithcytokinesanalysisofasingleinstitutionstudyon181patients
AT merrouchey patientswithmetastaticrenalcarcinomacandidateforimmunotherapywithcytokinesanalysisofasingleinstitutionstudyon181patients
AT carriec patientswithmetastaticrenalcarcinomacandidateforimmunotherapywithcytokinesanalysisofasingleinstitutionstudyon181patients
AT kaemmerlenp patientswithmetastaticrenalcarcinomacandidateforimmunotherapywithcytokinesanalysisofasingleinstitutionstudyon181patients
AT chauvinf patientswithmetastaticrenalcarcinomacandidateforimmunotherapywithcytokinesanalysisofasingleinstitutionstudyon181patients